The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
"The weight of evidence for IFN therapy seems simply overwhelming over the last year alone, never mind before that."
Unfortunately the weightiest bit of evidence for us was the failure of SPRINTER P3. That’s a big hurdle to overcome.
"Moving forward, J&J plans to focus on pre-exposure prophylaxis to flu, COVID-19"
Wouldn’t that rule us out?
Many thanks Nutkins
Fukurokuju79 said "I'm not convinced RMM would have had to issue an RNS against the gold streaming deal in q3 or even q4 as it was a commitment to fulfil gold supply on an annualised basis."
The RNS confirms that failure to deliver refined gold in Q3/Q4 22 is an event of default
Newgen might be the secured creditor but that doesn't mean they have control over the company's finances. Defaulting on their obligations to Elemental is a decision made by the company, not by Newgen. The company may well have been pressured by Newgen to divert the proceeds of gold sales to Newgen, but doing so has just led to two creditors after our blood rather than one. Elemental will be absolutely fuming. If the mine remains in operation there will not be a cent in it for shareholders.
In any case I think the main issue here is lack of transparency - the company is telling us in Feb 23 about a default that took place in Q3 22. There's No excuse for that.
I agree.
I’ve certainly written this off as a total loss.
Any thoughts, Yugo/Nonsence/Moon?
Oh dear.
Really extraordinary incompetence.
And on the significant shareholders page of the HZM webby it does say “Canaccord Genuity Wealth Management (Inst)" so it looks like Institutional side rather than private client portfolios.
Oops
Oh yes of course… Hargreave Hale (owned by Canaccord) run some of Marlborough’s funds, including, I think, the micro cap and nano cap funds. Silly old me. Forgot that.
I think this will turn out not to be the case
Yes it’s private client portfolios
Oh right, thanks Wasa
HZM is a UK issuer, ya? I think that means a holder has to report every move - up or down - through a round percentage point?
If the trade has pushed a significant shareholder through a reportable threshold it has to be reported regardless of where it has taken place
Might stir things up in the morning. If the MMs notice.....
This article was presented at the 2022 ERS International Congress, in session “ALERT 1: COPD and hospital management”.
"It would be a sale of the shares at say 75p a share"
Which shares?
Yep